Literature DB >> 27572472

Inhibitory effects of Shenkang injection and its main component emodin on the proliferation of high glucose‑induced renal mesangial cells through cell cycle regulation and induction of apoptosis.

Shouzhu Xu1, Yanying Lv2, Jing Zhao1, Junping Wang2, Xing Zhao2, Siwang Wang1.   

Abstract

Increased mesangial cell proliferation is a major pathological feature of early-stage diabetic nephropathy (DN). The present study investigated the effects of the Traditional Chinese Medicine Shenkang injection (SKI) and its main component emodin (EM) on high glucose‑cultured mesangial cells. The proliferation rate, cell cycle distribution, apoptosis and morphology of rat renal mesangial cells (RMCs) cultured in the presence of various concentrations of glucose (5.6 or 25 mM), SKI (25, 50 or 100 mg/l) or EM (10, 20 or 40 µM) were assessed at time‑points of 12, 24 or 48 h. High‑glucose treatment promoted the proliferation of RMCs, which was significantly inhibited by SKI and EM, while these drugs had no effect on RMCs under normal glucose conditions, as indicated by an MTT assay. Furthermore, flow cytometric analysis revealed that SKI and EM inhibited the cell cycle progression of RMCs and induced apoptosis. Transmission electron microscopy revealed morphological characteristics of apoptosis and western blot analysis demonstrated the upregulation of B‑cell lymphoma 2‑associated X protein (bax) and activation of caspases in RMCs following treatment with SKI or EM under high‑glucose conditions. In conclusion, SKI and its major active component EM were shown to inhibit high‑glucose‑induced proliferation of RMCs via inducing cell cycle arrest at G1 phase as well as cellular apoptosis via upregulation of pro‑apoptotic mediators bax and caspase activation, and may therefore be suitable for the treatment of DN.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27572472     DOI: 10.3892/mmr.2016.5631

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  7 in total

1.  ShenKang Injection Attenuates Renal Fibrosis by Inhibiting EMT and Regulating the Wnt/β-Catenin Pathway.

Authors:  Hui-Ting Wei; Yuan Xu; Xiao-Yang Tan; Hao-Yue Jing; Yue-Rong Ma
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-28       Impact factor: 2.650

2.  Shen-Kang protects against tacrolimus-induced renal injury.

Authors:  Long Ye Zhang; Jian Jin; Kang Luo; Shang Guo Piao; Hai Lan Zheng; Ji Zhe Jin; Sun Woo Lim; Bum Soon Choi; Chul Woo Yang; Can Li
Journal:  Korean J Intern Med       Date:  2018-02-12       Impact factor: 2.884

3.  Shenkang Injection and Its Three Anthraquinones Ameliorates Renal Fibrosis by Simultaneous Targeting IƙB/NF-ƙB and Keap1/Nrf2 Signaling Pathways.

Authors:  Liang-Pu Luo; Ping Suo; Li-Li Ren; Hong-Jiao Liu; Yamei Zhang; Ying-Yong Zhao
Journal:  Front Pharmacol       Date:  2021-12-22       Impact factor: 5.810

Review 4.  The progress and prospect of natural components in rhubarb (Rheum ribes L.) in the treatment of renal fibrosis.

Authors:  Yangyang Wang; Fangwei Yu; Ao Li; Zijia He; Caiyan Qu; Caiying He; Xiao Ma; Huakui Zhan
Journal:  Front Pharmacol       Date:  2022-08-29       Impact factor: 5.988

5.  Resveratrol provides benefits in mice with type II diabetes-induced chronic renal failure through AMPK signaling pathway.

Authors:  Haiyan Guo; Linyun Zhang
Journal:  Exp Ther Med       Date:  2018-05-17       Impact factor: 2.447

6.  Kidney-targeted drug delivery via rhein-loaded polyethyleneglycol-co-polycaprolactone-co-polyethylenimine nanoparticles for diabetic nephropathy therapy.

Authors:  Danfei Chen; Shunping Han; Yongqin Zhu; Fang Hu; Yinghui Wei; Guowei Wang
Journal:  Int J Nanomedicine       Date:  2018-06-19

7.  Efficacy and safety of Shenkang injection in the treatment of chronic renal failure: A protocol of a randomized controlled trial.

Authors:  JuXiang Mei; LingLing Yang; Deqin Wang; HaiXia Wang
Journal:  Medicine (Baltimore)       Date:  2021-12-03       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.